Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate.
Various purine and pyrimidine analogs and methotrexate were tested to determine whether they induce morphologic and functional myeloid differentiation in HL-60, a human promyelocytic leukemia cell line. Functional maturity was assessed by nitro blue tetrazolium reduction assays. 3-Deazauridine caused nearly all of the cells to differentiate during 6 days of treatment. Pyrazofurin, virazole, puromycin aminonucleoside, and the tricyclic nucleoside 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene induced maturation in 44-64% of the cells, whereas 5-azacytidine, 5-bromo-2'-deoxyuridine, 5-iodo-2' deoxyuridine, thymidine, and the antimetabolite methotrexate induced maturation in 28-36% of the cells. In terms of effective concentration, the most potent inducer was methotrexate (10-8 M). The predominant cell types after treatment with all of these compounds were the metamyelocyte and banded neutrophilic granulocyte.
D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D006801:Humans; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D008727:Methotrexate / Q000494:pharmacology*; D009580:Nitroblue Tetrazolium; D011684:Purine Nucleosides / Q000494:pharmacology*; D011741:Pyrimidine Nucleosides / Q000494:pharmacology*
D011684:Purine Nucleosides; D011741:Pyrimidine Nucleosides; D009580:Nitroblue Tetrazolium; D008727:Methotrexate